Trial Profile
Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Aspirin
- Indications Thrombosis
- Focus Therapeutic Use
- Acronyms DEA-LAA
- 28 Jul 2023 Planned End Date changed from 31 Dec 2022 to 30 Jun 2024.
- 28 Jul 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.
- 08 Jun 2022 Planned End Date changed from 31 Oct 2020 to 31 Dec 2022.